长链非编码 RNA 芯片分析在甲状腺乳头状癌中的应用。

Long Non-Coding RNAs Profiling Using Microarray in Papillary Thyroid Carcinoma.

机构信息

Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh.

Cancer Molecular Pathology of School of Medicine and Dentistry, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.

出版信息

Methods Mol Biol. 2022;2534:135-148. doi: 10.1007/978-1-0716-2505-7_10.

DOI:10.1007/978-1-0716-2505-7_10

PMID:35670973

Abstract

Long non-coding RNAs (lncRNAs) have been implicated in various cancers, including papillary thyroid carcinomas (PTCs). Genome-wide analysis (GWAS) of lncRNAs expression in PTC samples exhibited up and down regulation of lncRNAs, thus, acting as tumor promoting oncogenes or tumor suppressors in the pathogenesis of PTC by interacting with target genes. For example, lncRNAs such as HOTAIR, NEAT1, MALAT1, FAL1, HOXD-AS1, etc. are overexpressed in PTC in comparison to that of non-cancerous thyroid tissues, which stimulate the pathogenesis of PTC. On the other hand, lncRNAs such as MEG3, CASC2, PANDAR, LINC00271, NAMA, PTCSC3, etc. are down regulated in PTC tissues when compared to that of non-cancerous thyroid samples, suppressing formation of PTC. Also, several lncRNAs such as BANCR acts as oncogenic or tumor suppressor in PTC formation depending on which they are interacting with. In addition, lncRNAs expression in patients with PTC associated with clinicopathological parameters such as distance metastasis, lymph node metastasis, tumor size, pathological stage, and response to therapy. Thus, lncRNAs profiles could have the potential to be used as prognostic or predictive biomarker in patients with PTC. Therefore, we describe the microarray method to examine lncRNAs expression in PTC tissue samples, which could facilitate better management of patients with PTC. Furthermore, this method could be fabricated to examine lncRNAs expression in other biological and/or clinical samples.

摘要

长非编码 RNA（lncRNA）已被涉及到各种癌症，包括甲状腺乳头状癌（PTC）。对 PTC 样本中 lncRNA 表达的全基因组分析（GWAS）显示，lncRNA 的上调和下调，因此，通过与靶基因相互作用，作为肿瘤促进癌基因或肿瘤抑制因子，在 PTC 的发病机制中发挥作用。例如，lncRNAs 如 HOTAIR、NEAT1、MALAT1、FAL1、HOXD-AS1 等在 PTC 中表达高于非癌性甲状腺组织，刺激 PTC 的发病机制。另一方面，lncRNAs 如 MEG3、CASC2、PANDAR、LINC00271、NAMA、PTCSC3 等在 PTC 组织中表达下调与非癌性甲状腺样本相比，抑制 PTC 的形成。此外，一些 lncRNAs 如 BANCR 在 PTC 形成中作为癌基因或肿瘤抑制因子，这取决于它们与哪些基因相互作用。此外，lncRNA 的表达与 PTC 患者的临床病理参数有关，如远处转移、淋巴结转移、肿瘤大小、病理分期和对治疗的反应。因此，lncRNA 谱有可能作为 PTC 患者的预后或预测生物标志物。因此，我们描述了微阵列方法来检测 PTC 组织样本中的 lncRNA 表达，这可以帮助更好地管理 PTC 患者。此外，这种方法可以用于检测其他生物和/或临床样本中的 lncRNA 表达。